Tectonic Therapeutic (NASDAQ: TECX) had its price target lowered by analysts at Wells Fargo & Company from $112.00 to $101.00. They now have an "overweight" rating on the stock.
LowReport
Tectonic Therapeutic (NASDAQ: TECX) had its price target lowered by analysts at Wells Fargo & Company from $112.00 to $101.00. They now have an "overweight" rating on the stock.
Tectonic Therapeutic (NASDAQ: TECX) had its price target raised by analysts at Wells Fargo & Company from $79.00 to $112.00. They now have an "overweight" rating on the stock.
HighReport
Tectonic Therapeutic (NASDAQ: TECX) had its price target raised by analysts at Wells Fargo & Company from $79.00 to $112.00. They now have an "overweight" rating on the stock.
Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF [Yahoo! Finance]
HighReport
Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF [Yahoo! Finance]
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: